Ernexa Therapeutics Inc. Adjustments to Additional Paid in Capital, Warrant Issued
Ernexa Therapeutics Inc. (ERNA) reported Adjustments to Additional Paid in Capital, Warrant Issued of $11.24 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-03-13
- Ernexa Therapeutics Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-09-30 was $11.24M, a 119.91% increase year-over-year.
- Ernexa Therapeutics Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-06-30 was -$35.00K.
- Ernexa Therapeutics Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-03-31 was $755.00K.
- Ernexa Therapeutics Inc. adjustments to additional paid in capital, warrant issued for fiscal 2024 was $11.24M, a 24.74% increase from fiscal 2023.
- Ernexa Therapeutics Inc. adjustments to additional paid in capital, warrant issued for fiscal 2023 was $9.01M.
- Ernexa Therapeutics Inc. adjustments to additional paid in capital, warrant issued for fiscal 2013 was $1.38M.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $11.24M derived: sum of 2 quarters · filed 2026-03-13 | $11.21M derived: sum of 3 quarters · filed 2026-03-13 | $11.24M 10-K · filed 2026-03-13 |
| 2024-09-30 | $11.24M 10-Q · filed 2025-11-07 | $11.21M derived: sum of 2 quarters · filed 2025-11-07 | $11.24M 10-Q · filed 2025-11-07 | $15.87M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $720.00K 10-Q · filed 2025-08-13 | $4.62M derived: sum of 3 quarters · filed 2025-08-13 | $9.73M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $755.00K 10-Q · filed 2025-05-07 | $4.66M derived: sum of 2 quarters · filed 2025-05-07 | $9.77M derived: sum of 3 quarters · filed 2025-05-07 | |
| 2023-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $9.01M derived: sum of 2 quarters · filed 2024-03-14 | $9.01M 10-K · filed 2024-03-14 | |
| 2023-09-30 | $5.11M 10-Q · filed 2023-11-13 | $5.11M 10-Q · filed 2023-11-13 | ||
| 2013-12-31 | $1.38M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |